A 60-year-old man with fatigue and a perinephric mass was found to have Rosai–Dorfman disease expressing an activating mutation in KRAS. A course of therapy with oral cobimetinib produced a respons...
No takes yet. Share an insight, caveat, or question.
Jacobsen et al. (2017) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: